{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:16:42Z","timestamp":1758050202540,"version":"3.44.0"},"reference-count":7,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.bulcan.2021.07.010","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T17:14:02Z","timestamp":1634145242000},"page":"4-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nouvelle AMM europ\u00e9enne\u00a0: \u00ab\u00a0Nivolumab et ipilimumab, m\u00e9soth\u00e9liome pleural malin non r\u00e9s\u00e9cable en premi\u00e8re ligne\u00a0\u00bb"],"prefix":"10.1016","volume":"109","author":[{"given":"Quentin","family":"Laune","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solenn","family":"Brosseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2021.07.010_bib0040","doi-asserted-by":"crossref","first-page":"103278","DOI":"10.1016\/j.critrevonc.2021.103278","article-title":"Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: a systematic review and meta-analysis of randomized trials","volume":"160","author":"Lee","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"15_suppl","key":"10.1016\/j.bulcan.2021.07.010_bib0045","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1200\/JCO.2016.34.15_suppl.8554","article-title":"Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): a systematic review and meta-analysis","volume":"34","author":"Srour","year":"2016","journal-title":"JCO"},{"issue":"10026","key":"10.1016\/j.bulcan.2021.07.010_bib0050","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bulcan.2021.07.010_bib0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2021.07.010_bib0060","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cllc.2019.04.010","article-title":"Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the Bio-MAPS cohort","volume":"20","author":"Brosseau","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2021.07.010_bib0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10272","key":"10.1016\/j.bulcan.2021.07.010_bib0070","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512100374X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512100374X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:35:33Z","timestamp":1757792133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512100374X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S000745512100374X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.07.010","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nouvelle AMM europ\u00e9enne\u00a0: \u00ab\u00a0Nivolumab et ipilimumab, m\u00e9soth\u00e9liome pleural malin non r\u00e9s\u00e9cable en premi\u00e8re ligne\u00a0\u00bb","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}